by GOT | Jan 24, 2024 | News
Azurity Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Zenzedi® (dextroamphetamine sulfate tablets, USP) 30 mg Due to a Mislabeled Package During Manufacturing Media Contact: Liz Flynn, Director, Corporate Communications (781) 281-3225 FOR IMMEDIATE...
by GOT | Sep 27, 2023 | News
Azurity Pharmaceuticals Acquires Slayback Pharma MEDIA ALERT: WOBURN, MA, September 27, 2023 – Azurity Pharmaceuticals, Inc. (“Azurity”) is pleased to announce the closing of its acquisition of Slayback Pharma LLC (“Slayback”) today from existing investors...
by GOT | Oct 12, 2022 | News
AZURITY PHARMACEUTICALS, INC. ANNOUNCES U.S. AVAILABILITY OF ZONISADE™ (zonisamide oral suspension) MEDIA ALERT: WOBURN, MA, October 12, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the...
by GOT | Sep 2, 2022 | News
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) WOBURN, Mass. (September 2, 2022) – Azurity Pharmaceuticals, Inc., a pharmaceutical company focused on developing innovative dose-forms and...
by GOT | Jul 18, 2022 | News
AZURITY PHARMACEUTICALS, INC. ANNOUNCES FDA APPROVAL OF ZONISADE™ (zonisamide oral suspension) Woburn, Mass. – July 18, 2022 – Azurity Pharmaceuticals, Inc., a private pharmaceutical company focused on developing innovative products to serve the specific...
by GOT | Feb 18, 2022 | News
Azurity Pharmaceuticals Announces Richard Blackburn as New CEO Woburn, Mass. – February 18, 2022 – Azurity Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing innovative medicines that meet the specific needs of underserved...
Recent Comments